This brand name is authorized in France, Tunisia
The drug NIVAQUINE contains one active pharmaceutical ingredient (API):
|
1
Chloroquine
UNII OE48649K6N - CHLOROQUINE SULFATE
|
|
Chloroquine binds to and alters the properties of DNA. Chloroquine also binds to ferriprotoporphyrin IX and this leads to lysis of the plasmodial membrane. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| P01BA01 | Chloroquine | P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BA Aminoquinolines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 61551064, 65130778 |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 6390071B |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
